Oncternal Therapeutics Announces First Patient Dosed in Phase 1/2 Study of Dual-Action AR Inhibitor, ONCT-534, in Patients with Metastatic Castration-Resistant Prostate Cancer
05 oct. 2023 16h01 HE
|
Oncternal Therapeutics
SAN DIEGO, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal Therapeutics Announces its Prostate Cancer Scientific Advisory Board
07 sept. 2023 09h00 HE
|
Oncternal Therapeutics
SAN DIEGO, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2023 Financial Results
10 août 2023 16h01 HE
|
Oncternal Therapeutics
Obtained U.S. FDA IND clearance for ONCT-534, our dual-action androgen receptor inhibitor, for the treatment of patients with advanced prostate cancer who are resistant to approved androgen receptor...
Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results
03 août 2023 16h30 HE
|
Oncternal Therapeutics
SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal Therapeutics Receives FDA Study May Proceed Letter for ONCT-534, its Novel Dual-action Androgen Receptor Inhibitor, for the Treatment of Patients with Advanced Prostate Cancer
03 août 2023 16h05 HE
|
Oncternal Therapeutics
SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
30 juin 2023 16h30 HE
|
Oncternal Therapeutics
SAN DIEGO, June 30, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal Therapeutics Announces First Patient Dosed in Phase 1/2 Study of ROR1 targeting autologous CAR T, ONCT-808, in patients with relapsed or refractory aggressive B-cell lymphoma
06 juin 2023 16h01 HE
|
Oncternal Therapeutics
SAN DIEGO, June 06, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal Therapeutics to Participate at the 2023 Jefferies Healthcare Conference
31 mai 2023 17h00 HE
|
Oncternal Therapeutics
SAN DIEGO, May 31, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal Therapeutics Provides Business Update and Announces First Quarter 2023 Financial Results
04 mai 2023 16h01 HE
|
Oncternal Therapeutics
Phase 1/2 study initiated for ONCT-808, our autologous CAR-T targeting ROR1-expressing hematologic malignancies, with initial clinical data expected in late 2023Final IND-enabling studies completed...
Oncternal Therapeutics to Provide Business Update and Report First Quarter 2023 Financial Results
27 avr. 2023 17h00 HE
|
Oncternal Therapeutics
SAN DIEGO, April 27, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...